A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults

NCT07261371 | Completed Phase 1 FDA Drug

• 1 other identifier: C4951081
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess the bioequivalence (medicines that may have different names or be made in different ways, but have the same effect on the body) of different formulations of a CGRP receptor antagonist in healthy adult participants. The study is seeking participants who are:

1. 1.Healthy males and females 18 years of age or older
2. 2.Willing and able to comply with all scheduled visits, treatment plan, lifestyle considerations, and other study procedures.
3. 3.Body Mass Index of 16-32 kilogram per meter squared (kg/m2); and a total body weight \>45 kg

Conditions

Healthy Volunteer

Keywords

Healthy volunteers

Outcome Measures

Primary Outcomes (3)

• Area under the Plasma Concentration-Time profile from time 0 extrapolated to infinite time (AUCinf) of the test and reference formulations

  Pre-dose to 72 hours

• Area under the Plasma Concentration-Time profile from time 0 to time of last quantifiable data point (AUClast) of the test and reference formulations

  Pre-dose to 72 hours

• Maximum Observed Plasma Concentration (Cmax) of test and reference formulations

  Predose to 72 hours

Secondary Outcomes (1)

• Number of Participants with Treatment Emergent Adverse Events (TEAEs)

  Baseline up to 36 days after the last dose of study intervention

Study Arms (4)

Treatment Sequence 1 (Part 1)

EXPERIMENTAL

Drug: Test formulation (Treatment A); Drug: Reference formulation (Treatment B)

Treatment Sequence 2 (Part 1)

EXPERIMENTAL

Drug: Test formulation (Treatment A); Drug: Reference formulation (Treatment B)

Treatment Sequence 1 (Part 2)

EXPERIMENTAL

Drug: Test formulation (Treatment C); Drug: Test formulation (Treatment D)

Treatment Sequence 2 (Part 2)

EXPERIMENTAL

Drug: Test formulation (Treatment C); Drug: Test formulation (Treatment D)

Interventions

Test formulation (Treatment A) DRUG

calcitonin gene-related peptide receptor inhibitor

Treatment Sequence 1 (Part 1); Treatment Sequence 2 (Part 1)

Reference formulation (Treatment B) DRUG

calcitonin gene-related peptide receptor inhibitor

Treatment Sequence 1 (Part 1); Treatment Sequence 2 (Part 1)

Test formulation (Treatment C) DRUG

calcitonin gene-related peptide receptor inhibitor

Treatment Sequence 1 (Part 2); Treatment Sequence 2 (Part 2)

Test formulation (Treatment D) DRUG

calcitonin gene-related peptide receptor inhibitor

Treatment Sequence 1 (Part 2); Treatment Sequence 2 (Part 2)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and/or female participants must be 18 years of age or older (or the minimum age of consent in accordance with local regulations) at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.
• BMI of 16-32 kg/m2; and a total body weight \>45 kg.
• Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.

You may not qualify if:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
• Any medical, psychiatric condition, suicidal ideation and behavior, laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Use of prescription or nonprescription drugs and dietary and herbal supplements within 14 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.
• Previous administration of an investigational product (drug or vaccine) within 30 days or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.
• A positive urine drug test. A single repeat for positive drug screen may be allowed.
• Unwilling or unable to comply with the Lifestyle Considerations criteria of this study

Sponsors & Collaborators

• Pfizer: lead

Study Sites (1)

Pfizer Clinical Research Unit - New Haven

New Haven, Connecticut, 06511, United States

Location

Related Links

• To obtain contact information for a study center near you, click here.

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 21, 2025
• First Posted: December 3, 2025
• Study Start: November 24, 2025
• Primary Completion: April 22, 2026
• Study Completion: April 22, 2026
• Last Updated: May 4, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)